Sign In
Buy QLGN
$3.21
+0 (+0%)
At Close: Feb 17, 2026
Why IMARA Shares Are Trading Higher By Over 13%; Here Are 22 Stocks Moving Premarket
11:34am, Friday, 14'th Oct 2022 Benzinga
Gainers
Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares rose 80.1% to $0.4161 in pre-market trading after declining around 7% on Thursday. CONNEXA, last month, announced a $5.0 million private
Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium
08:30am, Thursday, 06'th Oct 2022
CARLSBAD, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers wi
Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session
04:16pm, Friday, 23'rd Sep 2022 Benzinga
Gainers
Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day ex
Qualigen Therapeutics Presents Data on QN-302 at AACR’s Pancreatic Cancer Meeting
09:02pm, Wednesday, 14'th Sep 2022 GlobeNewswire Inc.
Posters include data regarding 1) mode of action, and 2) preclinical toxicology
Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board
01:15pm, Thursday, 18'th Aug 2022 GlobeNewswire Inc.
CARLSBAD, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers w
Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
11:30am, Tuesday, 16'th Aug 2022 GlobeNewswire Inc.
Q2 2022 FastPack ® Sales increased approximately 28%, and gross profit on product sales was up 64% year-over-year from Q2 2021
Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
08:30am, Tuesday, 16'th Aug 2022
Q2 2022 FastPack ® Sales increased approximately 28%, and gross profit on product sales was up 64% year-over-year from Q2 2021 Milestone achievements in QN-302 and QN-247 oncology therapeutic program
This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving Premarket
11:50am, Wednesday, 03'rd Aug 2022 Benzinga
Gainers
Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on Tuesday.
Eargo, Inc. (NASDAQ: EAR) shares rose 148% to $1.74 in pre-ma
Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model
12:30pm, Monday, 01'st Aug 2022 GlobeNewswire Inc.
CARLSBAD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers w
3 Stocks Under $2 Insiders Are Aggressively Buying
12:26pm, Thursday, 23'rd Jun 2022 Benzinga
U.S. stocks traded lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around
Qualigen Therapeutics to Present at BIO International Convention
01:00pm, Tuesday, 14'th Jun 2022 GlobeNewswire Inc.
CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers w
Qualigen Therapeutics to Present at BIO International Convention
09:00am, Tuesday, 14'th Jun 2022
CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers wit
Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials
01:04pm, Tuesday, 07'th Jun 2022 GlobeNewswire Inc.
A Potential Treatment for Pancreatic Cancer in Addition to Other Tumors of High Unmet Clinical Need
Qualigen Therapeutics’ Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting
01:15pm, Thursday, 26'th May 2022 GlobeNewswire Inc.
Abstracts Highlight In Vitro and In Vivo Activity of Qualigen’s Pan-RAS inhibitor in (1) Pancreatic Cancer, and (2) Malignant Peripheral Nerve Sheath Tumors
Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference
01:15pm, Friday, 20'th May 2022 GlobeNewswire Inc.
CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers wi
